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Nigel J. Brand**, Manuel Palacı́n‡, Stefano Schiaffino§§, and Antonio Zorzano‡
From the ‡Parc Cientı́fic de Barcelona and Departament de Bioquı́mica i Biologia Molecular, Facultat de Biologia,
Universitat de Barcelona, Avda. Diagonal 645, E-08028 Barcelona, Spain, Department of Biomedical Sciences,
Consiglio Nazionale delle Ricerche Institute of Neurosciences, University of Padova, 35121 Padova, Italy,
§§Venetian Institute of Molecular Medicine, 35129 Padova, Italy, and **Department of Cardiothoracic Surgery,
National Heart and Lung Institute, Imperial College London, Dovehouse Street, London SW3 6LY, United Kingdom
We have reported a novel functional co-operation
among MyoD, myocyte enhancer factor-2 (MEF2), and the
thyroid hormone receptor in a muscle-specific enhancer
of the rat GLUT4 gene in muscle cells. Here, we demon-
strate that the muscle-specific enhancer of the GLUT4
gene operates in skeletal muscle and is muscle fiber-de-
pendent and innervation-independent. Under normal
conditions, both in soleus and in extensor digitorum lon-
gus muscles, the activity of the enhancer required the
integrity of the MEF2-binding site. Cancellation of the
binding site of thyroid hormone receptor enhanced its
activity, suggesting an inhibitory role. Muscle regenera-
tion of the soleus and extensor digitorum longus muscles
caused a marked induction of GLUT4 and stimulation of
the enhancer activity, which was independent of innerva-
tion. During muscle regeneration, the enhancer activity
was markedly inhibited by cancellation of the binding
sites of MEF2, MyoD, or thyroid hormone receptors. Dif-
ferent MEF2 isoforms expressed in skeletal muscle
(MEF2A, MEF2C, and MEF2D) and all members of the
MyoD family had the capacity to participate in the activ-
ity of the GLUT4 enhancer as assessed by transient trans-
fection in cultured cells. Our data indicate that the
GLUT4 enhancer operates in muscle fibers and its activ-
ity contributes to the differences in GLUT4 gene expres-
sion between oxidative and glycolytic muscle fibers and
to the GLUT4 up-regulation that occurs during muscle
regeneration. The activity of the enhancer is maintained
in adult muscle by MEF2, whereas during regeneration
the operation of the enhancer depends on MEF2, myo-
genic transcription factors of the MyoD family, and thy-
roid hormone receptors.
The GLUT4 glucose transporter gene is expressed mainly in
muscle and adipose cells. GLUT4 expression is exquisitely reg-
ulated in skeletal muscle so that its level determines the whole-
body glucose disposal in response to insulin. GLUT4 is differ-
entially expressed in oxidative and glycolytic muscle fibers in
the rat (1–3), undergoes up-regulation in muscle by thyroid
hormones (4–6), and is repressed by muscle denervation (7–9),
in experimental diabetes (2, 10, 11) or in response to cyclic
AMP treatment (12). In addition, agonists of AMP-activated
protein kinase enhance GLUT4 transcription in a muscle fiber-
dependent manner (13, 14).
As to the regulation of GLUT4 gene transcription, different
studies performed in transgenic mice have shown that a 5-
flanking region of 1154 bp in the GLUT4 gene is sufficient to
drive muscle-, heart-, and adipose tissue-specific GLUT4 ex-
pression (15, 16). In addition, several regulatory elements have
been identified within this region. Initial studies performed in
cultured muscle cells identified the region 522/402 as nec-
essary for muscle-specific expression and a myocyte enhancer
factor-2 (MEF2)1-binding site that was critical for its transcrip-
tional activity (17). Disruption of this MEF2-binding site ab-
lated tissue-specific GLUT4 expression in transgenic mice (18).
Recently, it has been suggested that the transcriptional co-
activator peroxisome proliferator activator protein- co-activa-
tor-1 participates in GLUT4 gene transcription by interacting
with MEF2 transcription factors (19). The Krüppel-like factor,
KLF15, binds to a site near the MEF2-binding element and
induces GLUT4 gene expression in 3T3-L1 cells (20).
Another relevant region is located at 742/712 relative to
the transcription initiation site. Different factors such as NF1
(nuclear factor I) (21) and a partially characterized protein (22)
bind to this region. NF1 seems to participate in the effects of
insulin on GLUT4 gene expression in adipose cells (21) and the
uncharacterized protein binding activity seems to interact with
the MEF2-binding site mentioned previously (22). In addition,
a region located between 125 and 112 of the mouse pro-
moter has been reported to bind a 96-kDa protein, which seems
to act as a repressor selectively in pre-adipocytes but not in
adipocytes (23).
We have reported tripartite co-operation between MyoD,
MEF2, and the thyroid hormone receptor (TR1) that takes
place in the context of an 82-bp muscle-specific enhancer in the
rat GLUT4 gene (at 502/420), which is active in both car-
diac and skeletal muscle (24). In the L6E9 skeletal muscle cell
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line and in 10T1/2 fibroblasts, a powerful synergistic activation
of the GLUT4 enhancer relied on the over-expression of MyoD,
MEF2, and TR1 and the integrity of their respective binding
sites. This is in keeping with the capacity of the E-box and the
thyroid response element (TRE) present in the enhancer to
bind MyoD and thyroid hormone receptors (24, 25). Further-
more, we have shown that in 10T1/2 fibroblasts, the forced
over-expression of MyoD, MEF2, and TR1 induces the expres-
sion of the endogenous, otherwise silent, GLUT4 gene (24).
In this study, we provide evidence that the 502/420 en-
hancer acts in skeletal muscle under in vivo conditions and
that its activity depends on the muscle fiber context, is up-
regulated during muscle regeneration, and is independent of
innervation.
MATERIALS AND METHODS
Reporter and Expression Vectors—The 502/420 TKCAT and the
502/420-pGL3-luciferase reporter constructs were obtained by the
annealing of three overlapping pairs of synthetic oligonucleotides that
encompassed the DNA sequence, comprising positions 502 to 420 in
the rat GLUT4 5-flanking region. The oligonucleotides flanking the
enhancer were designed so that upon annealing, cohesive BamHI ends
would be incorporated into both ends of the reconstituted enhancer to
allow the cloning into the BamHI-digested TKCAT or luciferase re-
porter vectors. All oligonucleotides were purchased from MWG Biotech
(Ebersberg, Germany). TKCAT, a gift from Dr. Nadal-Ginard (Cardio-
vascular Research Institute, New York Medical College, Valhalla, NY),
is a reporter vector that allows the analysis of putative transcriptionally
regulatory regions because of their effect on the basal transcription of
the CAT gene driven by the 109/51 region of the herpesvirus thy-
midine kinase gene (26). Mutant versions of the 502/420 enhancer,
which contained nucleotide substitutions in the sequence of putative
binding sites for known transcription factors, were made by substitut-
ing, in the annealing reaction, a new pair of oligonucleotides containing
the desired mutation for the wild type pair. The mutant forms of the
enhancer were subsequently cloned into the same BamHI site of the
TKCAT vector by the same method used for the wild type enhancer. The
sequence and orientation of the insert in all constructs was confirmed
by sequencing.
The expression vectors for mouse MyoD, mouse myogenin, and rat
muscle regulatory factor-4 (MRF4) were obtained from Dr. H.
Weintraub (Fred Hutchinson Cancer Research Center, Seattle,WA), Dr.
E. N. Olson (M. D. Anderson Cancer Center, Houston, TX), and Dr.
S. F. Konieczny (Purdue University, West Lafayette, IN), respectively.
The cDNA of human Myf5 obtained from ATCC was cloned into an
eukaryotic expression vector. The expression vectors for TR1 (pMT2-
TR1), MEF2A, MEF2C, and MEF2D were obtained from Dr. B. Nadal-
Ginard (Harvard Medical School, Boston, MA), Dr. P. Ruiz-Lozano
(University of California at San Diego, La Jolla, CA), Dr. J. McDermott
(York University, Toronto, Canada), and Dr. E.N. Olson (M. D.
Anderson Cancer Center), respectively.
Muscle Regeneration and Denervation—Muscle regeneration was in-
duced in 200–250-g male Wistar rats by intramuscular injection of
bupivacaine as described (27). Denervation was produced by cutting the
sciatic nerve high in the thigh.
Transfection of Regenerating and Adult Muscles—Regenerating in-
nervated or denervated soleus or extensor digitorum longus muscles
were injected with plasmid DNA (50 g) at day 3 after bupivacaine
treatment as described (27). We have shown previously that gene trans-
fer efficiency is high after DNA injection at day 3, when the regenerat-
ing muscle is composed mostly of small myotubes, but is very poor after
DNA injection at day 1, when only mononucleated myoblasts are pres-
ent (27). Muscles were removed at day 10 after injury (day 7 after
transfection) and frozen in isopentane cooled in liquid nitrogen. Adult
muscles were transfected by intramuscular injection of plasmid DNA
(20 g) followed by electroporation to increase gene transfer efficiency.
The electroporation procedure was similar to that described by Mir et
al. (28). Co-transfection of RSV-CAT or RSV-luciferase expression plas-
mids was used to normalize for transfection efficiency. Muscles were
removed at day 7 after transfection and frozen in isopentane cooled in
liquid nitrogen. Muscle extracts were obtained, and reporter gene ac-
tivity (luciferase and CAT) was measured by standard procedures. All
data were normalized for protein concentration on muscle extracts.
Cell Culture and Transfections—The C3H10T1/2 cell line (10T1/2)
was purchased from ATCC (Manassas, VA) and cultured as described
(29). Cells were transfected with the Fugene™ transfection enhancer
reagent (Roche Molecular Biochemicals) according to the manufactur-
er’s instructions. CAT activity was measured in cytoplasmic extracts as
described (29). Transfections with the CAT reporter vector included an
Escherichia coli -galactosidase expression vector (pON249) under the
control of the cytomegalovirus promoter (24). -Galactosidase activity
was measured in cytoplasmic extracts to determine the efficiency of
transfection. Protein concentration was measured with the BCA protein
assay reagent (Pierce). When T3 was administered to cells, medium
containing T3-depleted serum was used. T3-depleted serum was pre-
pared by anion-exchange chromatography as described (30).
Western Blotting—Western blotting was performed essentially as
described (9). Twenty-five g of membrane protein obtained from re-
generating or control muscles was loaded onto 10% SDS-polyacrylamide
gels to detect GLUT4 and the 1 subunit of the Na
-K-ATPase. Pro-
teins were detected by using specific antibodies.
RNA Isolation and Northern Blot Analysis—Total RNA was ex-
tracted using the acid guanidinium thiocyanate/phenol/chloroform
method as described by Chomczynski and Sacchi (31). All samples had
an A260/A280 ratio above 1.8. After quantification, total RNA (30 g) was
denatured at 65 °C in the presence of formamide, formaldehyde, and
ethidium bromide to allow the visualization of RNA. RNA was sepa-
rated on a 1.2% agarose-formaldehyde gel and blotted on Hybond N
filters. The RNA in gels and in filters was visualized with ethidium
bromide by UV transillumination to ensure the integrity of RNA, to
check the loading of equivalent amounts of total RNA, and to confirm
proper transfer. Northern blot was performed as reported (4). The rat
cDNA probe for GLUT4, a 2470-bp EcoRI fragment obtained from Dr.
M. Birnbaum (University of Pennsylvania), was labeled with [32P]dCTP
by random oligonucleotide priming.
RESULTS
The Muscle-specific Enhancer of the GLUT4 Gene Operates in
Skeletal Muscle under in Vivo Conditions and Is Muscle Fiber-
dependent—We have previously reported that the 502/420
enhancer regulates the transcriptional activity of the GLUT4
gene in muscle cells in culture (24). Here, we studied the
relevance of this enhancer under in vivo conditions in rat
skeletal muscle. In initial studies, the 502/420-TKCAT
plasmid or the parental promoter vector (as a control) were
transfected by electroporation into adult rat soleus (mainly
composed of slow-twitch oxidative muscle fibers) and extensor
digitorum longus (EDL) (mainly composed of fast-twitch glyco-
lytic muscle fibers) muscles. Our data indicate that the 502/
420 enhancer is operative under in vivo conditions both in
soleus and in EDL muscles and the activity of the enhancer was
about 7–11-fold that of the control vector (Fig. 1). The data also
indicate that the enhancer activity was significantly higher in
soleus muscle than in EDL (Fig. 1). Similar observations were
obtained after transfection with a plasmid 502/420-lucifer-
ase, i.e. the enhancer is operative in skeletal muscles, and
soleus showed a greater activity than EDL muscles (data not
shown). This is consistent with greater GLUT4 gene expression
in soleus compared with EDL muscles (1–3).
Muscle Regeneration Stimulates the Activity of the GLUT4
Enhancer—Damaged skeletal muscle is able to regenerate by
activation of satellite cells. These cells are quiescent under
basal conditions; however, their activation induced by trauma
causes proliferation and further differentiation into myotubes
and muscle fibers. The myogenic factors MyoD and Myf5 are
induced early during muscle regeneration, whereas MRF4 and
myogenin show a later induction (32). It has also been sug-
gested that during muscle regeneration, the activity of MEF2 is
enhanced (33). On this basis, we explored the impact of muscle
regeneration on GLUT4 enhancer activity. To this end, we
tested the enhancer activity in intact or regenerating soleus or
EDL muscles at day 7 after bupivacaine injection. Transfection
of the enhancer linked to the CAT reporter indicated a marked
stimulation (5-fold stimulation) of transcriptional activity dur-
ing regeneration (Fig. 2). Similar data were obtained when the
GLUT4 enhancer was linked to a luciferase reporter, i.e. activ-
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ity was enhanced 5-fold after muscle regeneration (data not
shown). Muscle regeneration also promoted marked stimula-
tion of the GLUT4 enhancer activity in EDL muscles (Fig. 2).
The GLUT4 Enhancer Activity Is Independent of Muscle In-
nervation—Muscle denervation causes a marked repression of
GLUT4 in skeletal muscles (7–9). Thus, we explored the effect
of denervation in the activity of the GLUT4 enhancer. To this
end, innervated or denervated soleus and EDL muscles were
transfected by electroporation with the 502/420-TKCAT
plasmid and reporter activity was assayed at day 7 (Fig. 3). No
significant differences were detected between innervated and
denervated groups in either soleus or EDL muscles (Fig. 3).
Under these conditions, GLUT4 expression was largely re-
duced by denervation in both muscle types (data not shown).
We also explored the effect of denervation on enhancer ac-
tivity in regenerating muscles. To this end, soleus or EDL
muscles were induced to regenerate in the absence or presence
of innervation. Reporter gene analyses in transfected muscles
indicated that the activity of the enhancer was again independ-
ent of innervation in both soleus and EDL muscles (Fig. 3).
Expression of GLUT4 in Regenerating Muscle—Based on the
regulatory pattern of the GLUT4 enhancer, we explored the
impact of muscle regeneration on GLUT4 expression. To this
end, soleus and EDL muscles were induced to regenerate by
bupivacaine injection in the absence or presence of innervation.
At different times of initiation of regeneration, muscles were
collected and GLUT4 protein and mRNA quantitated by West-
ern and Northern blot. We also processed in parallel muscles
from adult rats that were subjected to denervation for 7 days.
Expression of GLUT4 protein was very low after 3 days of
regeneration compared with adult levels (Fig. 4). GLUT4 pro-
tein markedly increased from day 3 to day 6 of regeneration
and remained relatively stable from day 6 to day 10 (Fig. 4).
Denervation did not prevent a robust induction of GLUT4
protein at day 6. However, denervation was associated to lower
levels of GLUT4 expression during the regeneration period
(Fig. 4). These effects were specific, and no substantial alter-
ation of the 1 subunit of the Na
-K-ATPase was detected
under these conditions (Fig. 4). An induction of GLUT4 mRNA
was also detected with regeneration, which was progressive
during time, so that maximal levels were attained only at day
10 (data not shown). In addition, maximal levels of GLUT4
mRNA at day 10 of regeneration were markedly lower in the
denervated group (data not shown). Thus, during muscle re-
generation GLUT4 is markedly induced and whereas an initial
GLUT4 induction wave is largely independent of innervation,
at later times it becomes dependent on muscle innervation.
Different Requirements of the Muscle-specific GLUT4 En-
hancer in Adult and in Regenerating Muscles—We studied the
active elements that were responsible for the activity of the
enhancer in adult and in regenerating muscles. In some stud-
ies, we transfected soleus and EDL muscles with different
mutant versions of the enhancer (i.e. mutations in the E-box,
the MEF2-binding site, or the TRE). Analysis in cultured cells
has demonstrated that the mutations used completely cancel
the three binding sites (24). Both in soleus and in EDL muscles
from adult rats, we detected a similar profile of changes to the
transcriptional output of the reporter (Fig. 5). Cancellation of
the E-box did not alter the transcriptional activity of the en-
hancer in soleus or EDL muscles. In contrast, mutation of the
MEF2-binding site caused a marked reduction of the activity of
the enhancer both in soleus and in EDL muscles (Fig. 5).
Mutation of the TRE doubled the transcriptional activity of the
enhancer in soleus and EDL muscles (Fig. 5), suggesting that
the thyroid hormone receptors may play a negative role in
adult muscles.
We also studied the requirements of the GLUT4 enhancer
during muscle regeneration. To this end, we transfected inner-
vated or denervated regenerating soleus or EDL muscles with
the different mutant versions of the enhancer. Cancellation of
the E-box or the TRE caused a marked reduction in the activity
of the enhancer in innervated or denervated regenerating so-
leus or EDL muscles (Figs. 6 and 7), which is in contrast to
what we found in adult muscle (Fig. 5). In keeping with the
observations in adult muscle, mutation of the MEF2-binding
site caused a marked reduction of the activity of the enhancer
FIG. 2. The muscle-specific GLUT4 enhancer (502/420) is
activated during muscle regeneration. Soleus and EDL muscles
from adult male rats or from regenerating muscles were transfected in
vivo with the 502/420-TKCAT construct together with a luciferase
reporter plasmid as a transfection control. After 7 days of transfection,
muscles were collected, extracts were obtained, and enzymatic activi-
ties were assayed. Results are the mean  S.E. from five observations/
group. *, statistically significant difference between adult muscle and
regenerating muscle, p  0.05.
FIG. 1. The muscle-specific GLUT4 enhancer (502/420) is
active in rat skeletal muscle in a fiber-dependent manner. Soleus
and EDL muscles from adult male rats were transfected in vivo by
electroporation with 20 g of empty vector (Control) and 20 g of the
502/420-TKCAT construct (Enhancer) along with a luciferase re-
porter plasmid as a transfection control. We collected muscles 7 days
after transfection to obtain extracts and further assay luciferase and
CAT activity. CAT activity was corrected by luciferase activity and
protein and expressed as values relative to control (empty vector) ac-
tivity. Results are the mean  S.E. of at least 10 observations/group. *,
statistically significant difference between soleus and EDL muscles,
p  0.05.
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in innervated or denervated regenerating soleus or EDL mus-
cles (Figs. 6 and 7).
Different MEF2 Isoforms or MRF Myogenic Proteins Operate
on the GLUT4 Enhancer—We have previously shown that
MEF2A and MyoD transactivate the muscle-specific GLUT4
enhancer and that MEF2A synergizes with MyoD and TR1 on
the activity of the enhancer in muscle and non-muscle cells
(24). Based on the role of the E-box and the MEF2 element in
the control of the activity of the muscle-specific GLUT4 en-
hancer in the muscle fiber under different conditions, we stud-
ied whether other MEF2 isoforms expressed in muscle, i.e.
MEF2C and MEF2D (34), or other MRF myogenic factors, i.e.
myogenin, Myf5, or MRF4, also transactivate the enhancer.
In some studies 10T1/2 cells were transiently transfected
with MEF2A, MEF2C, or MEF2D either alone or in combina-
tion with TR1 and/or MyoD (Fig. 8A). MEF2A, MEF2C, and
MEF2D behaved similarly when transfected on their own (3–
4-fold induction) (Fig. 8A). In addition, all MEF2 isoforms
synergized with MyoD and TR1 (Fig. 8A). Under these condi-
tions, MEF2C was most efficient in synergizing with TR1 or
with MyoD plus TR1 (Fig. 8A). This was followed by MEF2A
and MEF2D (Fig. 8A). We also tested whether co-transfection
with different MEF2 isoforms could modify, through the gen-
eration of heterodimers, the functional tripartite cooperativity
with MyoD or TR1. Transfection of cells with expression vec-
tors for MEF2A and MEF2D in the presence of MyoD and TR1
activated the enhancer up to levels comparable with MEF2A,
which were greater than the values obtained in the presence of
MEF2D (Fig. 8B). Similarly, transfection with MEF2C and
MEF2D in the presence of MyoD and TR1 raised the enhancer
activity up to values similar to those of the MEF2C group and
again greater than the values of the MEF2D group (Fig. 8C).
In other experimental series, we transiently co-transfected
10T1/2 cells with different combinations of cDNA expression
vectors for members of the MyoD family of MRF, MEF2A, and
TR1. In some experiments we used MyoD or myogenin as
MRF proteins and in other experiments MyoD or MRF4 (Fig.
9). Myogenin and MRF4 transfected on their own showed a
moderate activation of the enhancer, which was comparable
with the effect of MyoD (Fig. 9). Transfection of TR1 caused a
repression of the enhancer when cells were maintained in the
absence of T3 (data not shown), whereas a substantial activa-
tion was detected in the presence of T3 (Fig. 9). In addition, and
most importantly, both myogenin and MRF4 activated the en-
hancer synergistically with TR1 and with TR1 plus MEF2A
(Fig. 9). The synergistic effect displayed by myogenin or
MRFR4 was similar to that of MyoD (Fig. 9). Myf5 behaved
similarly (data not shown). Furthermore, we examined
whether the effects of myogenin synergizing with TR1 in
FIG. 3. The activity of the muscle-
specific GLUT4 enhancer (502/
420) is independent of innervation.
Adult and regenerating soleus and EDL
muscles were transfected with the 502/
420-CAT construct together with a lu-
ciferase reporter plasmid as a trans-
fection control. Simultaneous with trans-
fection, muscles were denervated (Den) by
sciatic nerve sectioning, or they remained
innervated (In). Seven days after trans-
fection, muscles were collected, extracts
were obtained, and luciferase and CAT
activity were assayed. Specific CAT activ-
ity was expressed as a percentage of ac-
tivity in the innervated groups. Results
are mean  S.E. from five observations/
group. Differences between innervated
and denervated muscles were not statis-
tically significant.
FIG. 4. GLUT4 expression is induced during muscle regenera-
tion. Total membrane fractions were obtained from control (C), dener-
vated, regenerating (IN) or regenerating-denervated (DEN) soleus
(panel A) or extensor digitorum longus muscles (panel B). Denervation
of adult nonregenerating muscle was done 7 days prior to muscle
collection. Muscle regeneration was studied on days 3, 6, and 10. Total
membranes were subjected to SDS-PAGE and further immunoblotting
using specific antibodies directed against GLUT4 or the 1 subunit of
Na-K-ATPase. Panels show representative autoradiograms.
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FIG. 5. Effect of mutations in the E-
box, MEF2, and TRE on the activity
of the muscle enhancer in adult rat
skeletal muscles. Soleus and EDL mus-
cles from adult male rats were in vivo
transfected by electroporation with 502/
420-TKCAT constructs containing ei-
ther the wild type enhancer (Enh) or mu-
tated versions at the E-box, MEF2 box, or
TRE together with a luciferase reporter
plasmid as a transfection control. After 7
days of transfection, muscles were col-
lected, extracts were obtained, and enzy-
matic activities were assayed. CAT activ-
ity was expressed as a percentage of wild
type enhancer activity. Results are
mean  S.E. from five observations/
group. *, statistically significant differ-
ence compared with the wild type en-
hancer group, p  0.05.
FIG. 6. Effect of mutations in the E-
box, MEF2, and TRE on the activity
of the muscle enhancer in regenerat-
ing soleus muscle. Soleus muscles from
regenerating muscles were in vivo trans-
fected with 502/420TK-CAT con-
struct, containing either the wild type en-
hancer (Enh) or mutated versions at the
E-box, MEF2 box, or TRE together with a
luciferase reporter plasmid as a transfec-
tion control. After 7 days of transfection,
muscles were collected, extracts were ob-
tained, and enzymatic activities were as-
sayed. CAT activity was expressed as a
percentage of wild type enhancer activity.
Results are the mean  S.E. from five
observations/group. *, statistically signif-
icant difference compared with the wild
type enhancer group, at p  0.05.
FIG. 7. Effect of mutations in the E-
box, MEF2, and TRE on the activity
of the muscle enhancer in regenerat-
ing extensor digitorum longus mus-
cle. EDL muscles from regenerating mus-
cles were transfected in vivo with the
502/420TK-CAT construct containing
either the wild type enhancer (Enh) or
mutated versions at the E-box, MEF2 box,
or TRE together with a luciferase reporter
plasmid as a transfection control. After 7
days of transfection, muscles were col-
lected, extracts were obtained, and enzy-
matic activities were assayed. CAT activ-
ity was expressed as a percentage of wild
type enhancer activity. Results are the
mean  S.E. from five observations/
group. *, statistically significant differ-
ence compared with the wild type en-
hancer group, p  0.05.
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activating the enhancer were dependent on the integrity of the
E-box, as we have previously reported for MyoD (24). Thus,
transient co-transfection studies were done using either a wild
type or a mutated version of the enhancer plus a combination of
expression vectors for the transcription factors. Data indicated
that both the effects of myogenin or MyoD on the enhancer
activity as well as the synergy between myogenin and TR1 or
MyoD and TR1 were abolished by mutating the E-box (data
not shown). Altogether, these data demonstrate that the integ-
rity of the E-box is required for the effects of the MRF protein
family on the activity of the muscle-specific GLUT4 enhancer
and reveal the existence of the functional redundancy of the
different members of the MRF family synergizing with MEF2
and TR1 on the muscle-specific GLUT4 enhancer.
DISCUSSION
The results of this study indicate that the muscle-specific
GLUT4 enhancer located at 502/420 operates under in vivo
conditions in maintaining the expression of GLUT4 in skeletal
muscle, contributes to the differences in GLUT4 expression
detected in glycolytic and oxidative muscle fibers, and is acti-
vated in regenerating muscles under conditions in which
GLUT4 is induced. In adult muscle, the activity of the enhancer
requires an intact MEF2-binding site, and the TREs play an
inhibitory role. However, during muscle regeneration, the
MEF2 site, the E-box, and the TREs are crucial in maintaining
a high activity. On the other hand, the activity of the enhancer
is independent of muscle innervation both in adult muscle and
during muscle regeneration.
We have previously demonstrated that the muscle-specific
GLUT4 enhancer is activated synergistically by MyoD, MEF2,
and TR1 in muscle and nonmuscle cells in culture and that
this requires the integrity of the respective DNA-binding ele-
ments (24). In addition, mutation of the MEF2-binding element
or the TRE caused a reduction of transcriptional output in
cultured cardiomyocytes (24). In this study, we show that in
adult skeletal muscle, under normal conditions, the activity of
the muscle-specific GLUT4 enhancer is essentially maintained
by the MEF2-binding element, and so cancellation of the ele-
FIG. 8. MEF2A, MEF2C, and MEF2D synergize with MyoD and TR1 in the trans-activation of the GLUT4 502/420 TKCAT reporter
system. 10T1/2 fibroblasts were transfected with 100 ng of the 502/420 TKCAT construct and 50 ng of expression vectors for MyoD, MEF2A,
MEF2C, MEF2D, or TR1 with Fugene™ reagent. T3 at a final concentration of 100 nM was added to cells to which TR1 had been transfected. Cells
were harvested 36 h after transfection. A, co-transfections were done by combining MyoD and TR1 with MEF2A (filled bars), MEF2C (open bars), or
MEF2D (hatched bars). Data are the means  S.E. of relative CAT activity over basal 502/420 TKCAT levels from seven independent experiments
performed in triplicate. Basal levels showed an enzymatic activity of 3.9  0.5 nmol of acetylated chloramphenicol/g of protein/h and was 3.8 times
above background (CAT activity in non-transfected cells). *, significantly different from the MEF2C group, p  0.05. #, a significant difference between
the MEF2A and MEF2D groups, p  0.05. B shows the results obtained by transfecting with MEF2A (filled bars), MEF2D (open bars), or MEF2A and
MEF2D (hatched bars). Data are the means  S.E. of relative CAT activity over basal 502/420 TKCAT levels from seven independent experiments
performed in triplicate. *, significantly different from the MEF2A group, p  0.05. #, significantly different from the MEF2A/MEF2D group, p  0.05.
C shows the results obtained by transfecting with MEF2C (filled bars), MEF2D (open bars), or MEF2C and MEF2D (hatched bars). *, significantly
different from the MEF2C group, p  0.05. #, significantly different from the MEF2C/MEF2D group, p  0.05.
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ment causes a major repression of activity. In addition, we have
found that the enhancer is subjected to repression via the TRE,
so that its cancellation doubles the activity of the enhancer.
The relevance of the MEF2-binding site was also reported in a
study using transgenic mice, in which a marked repression of
the transcriptional activity driven by 895 bp of DNA encom-
passing the 5-flanking region of GLUT4 gene was detected in
adipose tissues or in muscles after mutation of the MEF2-
binding site (18). It is surprising to find that the TRE inhibits
the activity of the enhancer under normal conditions in adult
muscle because: on the one hand, the administration of T3 to
rats is known to cause the induction of GLUT4 gene expression
in certain muscle types (5, 6); in addition, the concentration of
T3 in rat skeletal muscle lies within the nanomolar range (35),
i.e. high enough to activate to some degree thyroid hormone
receptors. In any case, the reason that the muscle-specific
GLUT4 enhancer remains inhibited through the TRE in skel-
etal muscle remains unexplained.
In contrast with adult muscle, muscle regeneration caused a
dramatic change in the mode of operation of the GLUT4 en-
hancer. Thus, during muscle regeneration, cancellation of the
three elements detected previously, i.e. the MEF2-binding site,
the E-box, and the TRE, blocked the activity of the enhancer,
consistent with the idea that they play an stimulatory role
under those conditions.
The different pattern shown by the GLUT4 enhancer indi-
cates that the E-box of the enhancer remains inactive in adult
skeletal muscle, whereas it is operative in regenerating muscle.
This is consistent with the low expression of MRFs in skeletal
muscle during adult life (36, 37) and with their induction dur-
ing regeneration (32). In addition, our data suggest a powerful
inhibitory effect of the TRE in adult muscle and a stimulatory
role during regeneration.
A corollary of the activity profile of the muscle-specific
GLUT4 enhancer is that its activity is low in adult skeletal
muscle, under normal conditions, compared with the maximal
potential activity that it can attain at high levels of the MRF
transcription factors, MEF2, and TR1. This suggests the pos-
sibility of major up-regulation of GLUT4 gene transcription via
activation of this enhancer by an increase in the levels of
expression or activity of such transcription factors.
We have observed that the activity of the enhancer is greater
in soleus than in EDL muscles, which helps to explain the
differences in GLUT4 gene expression and gene transcription
that exist between oxidative and glycolytic muscles (1–3). We
found that the profile of changes in the activity of the enhancer
in response to mutations in the E-box, MEF2 site, or TRE was
similar in both muscle types. These data suggest that oxidative
muscles show a greater activity of the muscle-specific GLUT4
enhancer than glycolytic muscles as a consequence of a greater
activity of the MEF2-binding site. This is in keeping with
observations indicating that the soleus muscle displays a
greater expression of MEF2A and MEF2D and a lower phos-
phorylation level and greater activity than proteins obtained
from gastrocnemius muscle (38).
The damage of skeletal muscle triggers the activation of
otherwise quiescent satellite cells. These are mononucleated
stem cells that are situated between the basal lamina of the
extracellular matrix and the plasma membrane of muscle fi-
bers. After proliferation, satellite cells exit the cell cycle and
FIG. 9. MyoD, myogenin, and MRF4
synergize with MEF2A and TR1 in
the GLUT4 502/420 TKCAT re-
porter system. 10T1/2 fibroblasts were
transfected with 100 ng of the 502/420
TKCAT construct and 50 ng of expression
vectors for MyoD, myogenin, MRF4,
MEF2A, or TR1 with Fugene™ reagent.
T3 at a final concentration of 100 nM was
added to cells when TR1 was trans-
fected. Cells were harvested 36 h after
transfection. Data are the means  S.E.
of relative CAT activity over basal 502/
420 TKCAT levels from six independent
experiments performed in triplicate. A
shows results obtained by transfection
with myogenin (Myog) or MyoD. B shows
results obtained by transfection with
MRF4 or MyoD.
GLUT4 Gene Transcription in Skeletal Muscle 40563
fuse, forming multinucleated myotubes, which replace the
damaged muscle fibers. We provide evidence that muscle re-
generation induced after bupivacain treatment causes a dra-
matic induction of GLUT4 expression, which is consistent with
the fact that GLUT4 is induced along with myogenesis in
cultured cells (29, 39). This finding coincides with a very strong
stimulation of the muscle-specific GLUT4 enhancer relative to
the intact muscle and with the functional operation of all three
elements (MEF2, E-box, and TRE). We propose that under
these conditions, the enhancer is activated via induction of
myogenic MRFs (32, 40) and by activation of the MEF2 factors
(33). In this regard, we have demonstrated that all members of
the MRF protein family are equally able to cooperate function-
ally with MEF2 and thyroid hormone receptors in the context
of the muscle-specific GLUT4 enhancer. Based on the fact that
muscle regeneration recapitulates muscle development, it is
possible that the muscle-specific GLUT4 enhancer participates
in the progressive induction of GLUT4 that occurs during peri-
natal development in skeletal muscle (4, 41, 42).
It is well known that muscle denervation causes a dramatic
repression of muscle GLUT4 gene expression (7–9) because of
repressed transcription (43). In this study, we have clearly
shown that muscle denervation is not detrimental to the activ-
ity of the muscle-specific GLUT4 enhancer either in soleus or in
EDL muscles, but we have detected a trend to increased activ-
ity. In addition, during muscle regeneration, the lack of inner-
vation at an early stage (day 6 of regeneration) did not prevent
the induction of GLUT4 protein, whereas denervation caused a
marked down-regulation of GLUT4 expression later on. Never-
theless, regenerating denervated muscles did not display any
alteration in the activity of the muscle-specific GLUT4 en-
hancer. Taken together, these data indicate that the muscle-
specific GLUT4 enhancer does not play a role in the down-
regulation of GLUT4 gene expression that occurs during
muscle denervation or the down-regulation that occurs late
during muscle regeneration. Tsunoda et al. (44) have mapped
the region of the GLUT4 gene involved in the regulation of
GLUT4 transcription by muscle denervation, which lies 3 to
position 423 (42) and is therefore outside of the muscle-
specific GLUT4 enhancer.
In summary, our study indicates that the muscle-specific
GLUT4 enhancer operates at a low level in intact adult muscle.
In addition, it constitutes a switch that turns on GLUT4 tran-
scription under conditions associated with GLUT4 induction,
such as during muscle regeneration, possibly during myogen-
esis, and in the early phases of the development of skeletal
muscle, e.g. in situations characterized by a high expression of
myogenic factors, MEF2, and thyroid hormone receptors. In
adult skeletal muscle and under normal conditions, the en-
hancer operates at a low rate, driven by MEF2 transcription
factors and inhibited by the TRE, and participates in the dif-
ferences in GLUT4 gene expression between oxidative and
glycolytic muscle fibers. In regenerating muscle, the enhancer
operates at a high rate, driven by MEF2, MRFs, and thyroid
hormone receptors. Under all of these conditions, the activity of
the enhancer is independent of muscle innervation.
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